Making Drugs From Fragments

Making Drugs From Fragments : Starting Simple and Keeping it Simple

By (author) 

Free delivery worldwide

Available soon, pre-order now.
When will my order arrive?

42 days to go
Pre-order Add to wishlist


Making Drugs from Fragments: Starting Simple and Keeping It Simple is both a practical tool for chemists and an accessible guide for their managers on the best ways to implement and optimize fragment-based drug design in their work.

As a method that offers great benefits in terms of economic viability, rapidity of results, and good success rates, fragment-based drug design has quickly been embraced by the drug discovery community. Combining strong coverage of foundational knowledge with expert tips and techniques, this book is designed to provoke new ideas and discussion amongst seasoned professionals, while also helping those in non-scientific roles evaluate the opportunities and benefits of implementing fragment-based design at their organizations.

Beginning with an introduction to the rules and metrics of fragment-based lead discovery and how to assess their usefulness, the book then reviews methods for prioritizing targets, designing fragment libraries, and the potential for combining fragment-based methods with high-throughput screening for the benefit of both.

In addition, users will find sections on methods for taking simple fragments and optimizing them to simple drug-like candidates and a practical overview of why fragments might not develop and optimize as expected. Finally, the book concludes by asking if processes and accumulated data can be simplified and standardized to increase the efficiency of fragment-based drug discovery.
show more

Product details

  • Paperback | 336 pages
  • 152 x 229mm
  • United States
  • English
  • 0128096772
  • 9780128096772

Table of contents

1. Introduction: The elegant simplicity of FBLD - starting small and staying small 2. Rules and metrics to guide FBLD: The good the bad and the ugly 3. Prioritizing targets for FBLD 4. Library design with an eye towards making a marketed drug 5. Can HTS and FBLD be friends? 6. Finding fragment hits: seeing the forest and the trees 7. The golden ticket? When fragments create their own binding site 8. Ligand efficiency and fragment growing 9. Fragment growing: Why didn't all my fragments optimize? The structures say they should 10. Parallel processing of fragment hits: making a drug is not just about potency
show more

About Vicki Nienaber

Dr Nienaber is a pioneer in this field and has been actively involved for the past 20 years. After graduating from The Ohio State University (USA) and completing her PhD whilst working at DuPont-Merk, she went on to build the crystallography driven first fragment screening platform at Abbott Laboratories in the mid 1990s. Following this, she implemented fragment screening at SGX pharma and ran their internal fragment-driven lead discovery program, taking the program from fragment to clinical candidate. In 2008, Vicki founded Zenobia Therapeutics to apply Fragment Based Lead Discovery to CNS disease and has most recently built the foundation for a products division and centre of excellence to support fragment-based lead discovery. Her historic perspective and contacts make her the ideal editor for this project.
show more